NCT07091695Completed
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab (Nivo+Rela) or Nivolumab+Ipilimumab (Nivo+Ipi)
Source: ClinicalTrials.gov · Last updated 12 Nov 2025
Brief summary (registry, in English)
The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the real-world use of neoadjuvant nivolumab+relatlimab or nivolumab+ipilimumab
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 22 Jul 2025
- Start date
- 11 May 2025
- Primary completion date
- 6 Nov 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Melanoma
- NCT number
- NCT07091695
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 11 May 2025 to the primary completion date, 6 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants received nivo+rela or nivo+ipi for clinically palpable stage III resectable melanoma as part of a therapeutic clinical trial
- Participants received adjuvant nivo+rela or adjuvant nivo+ipi after neoadjuvant nivo+ipi
- Participants received adjuvant nivo+ipi after neoadjuvant nivo+rela
- Participants received any systemic therapy prior to the initiation of neoadjuvant nivo+rela or nivo+ipi
Other illness
- Participants had history of diagnosis of any malignancy (except for non-melanoma skin cancer) in the last 2 years.
Who the study is looking for
- Participants at least 18 years old at diagnosis of clinically palpable stage III resectable melanoma
- Participants treated with nivolumab+relatimab (nivo+rela) or nivolumab+ipilimumab (nivo+ipi) in the neoadjuvant setting
- Participants with at least 6 months of follow-up from initiation of neoadjuvant therapy, unless deceased prior to 6 months of follow-up
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cardinal Health Coordinator of this site? Confirm its status | Dublin | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.